Erratum: CXCR3 ligands as clinical markers for pulmonary tuberculosis (International Journal of Tuberculosis and Lung Disease (2015) 19:2 (191-199) DOI: 10.5588/ijtld.14.0525);CXCR3 ligands as clinical markers for pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 2, 2015, Pages 191-199

  Lee, K ^a   Chung, W ^a   Jung, Y ^a   Kim, Y ^a   Park, J ^a   Sheen, S ^a   Park, K ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Biological markers; Cell mediated immunity; Chemokine receptors; CXC chemokine; Interferon c

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; BIOLOGICAL MARKER; CXCR3 PROTEIN, HUMAN; LIGAND;

ACID FAST BACTERIUM; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; THORAX RADIOGRAPHY; AGED; BLOOD; CASE CONTROL STUDY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; SPUTUM; TUBERCULOSIS, PULMONARY; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERFERON-GAMMA; LIGANDS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, CXCR3; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 84937128811     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0525-e     Document Type: Erratum

References (33)

1. Wallis R S, Kim P, Cole S, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis 2013; 13: 362-372.
2. Wallis R S, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-1937.
3. Lawn S D, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert® MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013; 13: 349-361.
4. Sutherland J S, Hill P C, Adetifa I M, et al. Identification of probable early-onset biomarkers for tuberculosis disease progression. PLOS ONE 2011; 6: e25230.
5. Brahmbhatt S, Black G F, Carroll N M, et al. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin Exp Immunol 2006; 146: 243-252.
6. Steingart K R, Flores L L, Dendukuri N, et al. Commercial serological tests for the diagnosis of active pulmonary and extra-pulmonary tuberculosis: an updated systematic review and meta-analysis. PLOS MED 2011; 8: e1001062.
7. Berry M P, Graham C M, McNab F W, et al. An interferoninducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-977.
8. Agranoff D, Fernandez-Reyes D, Papadopoulos M C, et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006; 368: 1012-1021.
9. Weiner J 3rd, Parida S K, Maertzdorf J, et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLOS ONE 2012; 7: e40221.
10. Mihret A, Bekele Y, Bobosha K, et al. Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J Infect 2013; 66: 357-365.
11. Yu Y, Zhang Y, Hu S, et al. Different patterns of cytokines and chemokines combined with IFN-gamma production reflect Mycobacterium tuberculosis infection and disease. PLOS ONE 2012; 7: e44944.
12. Sakai S, Kauffman K D, Schenkel J M, et al. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J Immunol 2014; 192: 2965-2969.
13. Koguchi Y, Kawakami K, Uezu K, et al. High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T-helper cell response in tuberculosis. Am J Respir Crit Care Med 2003; 167: 1355-1359.
14. Andersen P, Munk M E, Pollock J M, et al. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356: 1099-1104.
15. Sester M, Sotgiu G, Lange C, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37: 100-111.
16. Groom J R, Luster A D. CXCR3 in T cell function. Exp Cell Res 2011; 317: 620-631.
17. Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008; 32: 1607-1615.
18. Hong J Y, Jung G S, Kim H, et al. Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis. Int J Infect Dis 2012; 16: e855-e859.
19. Cole K E, Strick C A, Paradis T J, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-2021.
20. Loetscher P, Pellegrino A, Gong J H, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001; 276: 2986-2991.
21. Chung W Y, Lee K S, Jung Y J, et al. A tuberculosis antigenstimulated CXCR3 ligand assay for the diagnosis of active pulmonary tuberculosis. Chest 2014; 146: 283-291.
22. Falk A, O'Connor J B, Pratt P C, eds. Diagnosis standards and classification of tuberculosis. New York, NY, USA: National Tuberculosis and Respiratory Disease Association, 1969: pp 68-76.
23. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-1395.
24. Pepe MS, Thompson ML. Combining diagnostic test results to increase accuracy. Biostatistics 2000; 1: 123-140.
25. Ottenhoff T H. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 2012; 20: 419-428.
26. Arlehamn C L, Seumois G, Gerasimova A, et al. Transcriptional profile of tuberculosis antigen-specific T-cells reveals novel multifunctional features. J Immunol 2014; 193: 2931-2940.
27. Azzurri A, Sow O Y, Amedei A, et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microb Infect 2005; 7: 1-8.
28. Riou C, Perez Peixoto B, Roberts L, et al. Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLOS ONE 2012; 7: e36886.
29. Alessandri A L, Souza A L, Oliveira S C, et al. Concentrations of CXCL8, CXCL9 and sTNFR1 in plasma of patients with pulmonary tuberculosis undergoing treatment. Inflam Res 2006; 55: 528-533.
30. Muller M, Carter S, Hofer M J, et al. The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity-a tale of conflict and conundrum. Neuropathol Appl Neurobiol 2010; 36: 368-387.
31. Lohmann E M, Koster B F, le Cessie S, et al. Grading of a positive sputum smear and the risk of Mycobacterium tuberculosis transmission. Int J Tuberc Lung Dis 2012; 16: 1477-1484.
32. Rotondi M, Lazzeri E, Romagnani P, et al. Role for interferongamma inducible chemokines in endocrine autoimmunity: an expanding field. J Endocrinol Invest 2003; 26: 177-180.
33. Tworek D, Kuna P, Mlynarski W, et al. MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis. Arch Medical Sci 2013; 9: 849-853.